BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Products » Market Size Determination for the Cell Therapy CDMO Market
Cell Therapy CDMO Market Size

Market Size Determination for the Cell Therapy CDMO Market

Category: Uncategorized Tags: cell therapy, manufacturing
  • Description

Description

20 Page Market Brief; October 2017

Among cell therapy companies, the pressure for manufacturing innovation and optimization can incentivize them to seek third-party partners who possess technical, manufacturing, and regulatory expertise, such as cell therapy contract and development manufacturing organizations (CDMOs).

Discover class-defining bioproduction tools.

Benefits of partnering with a cell therapy CDMO include scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies. With more than two dozen market participants now offering cell therapy CDMO services, demand for these services is clearly expanding.

For this reason, we released a 20 page market brief that defines the size of the Cell Therapy CDMO Market and provides future market projections.

It reveals the…

  1. Top 3 market leaders (that control nearly 50% of the market share)
  2. Relative size of each market participant
  3. Size of the Cell Therapy CDMO Market
  4. Projections for the Cell Therapy CDMO Market through 2022

Cell therapy CDMOs featured in this analysis include:

  1. WuXi PharmaTech, including Subsidiary WuXi AppTech, Inc.
  2. Lonza, Cell Therapy Manufacturing Unit – Acquired PharmaCell, B.V. in May 2017
  3. Hitachi Chemical Advanced Therapeutics Solutions (HCATS)/PCT – HCATS acquired PCT March 2017
  4. MasTHerCell – Acquired by Orgenesis
  5. Miltenyi Bioprocess, the Contract Manufacturing Business of Miltenyi Biotec
  6. Nikon CeLL innovation Co., Ltd. (“NCLi”), a wholly-owned subsidiary of Nikon Corporation
  7. KBI Biopharma – Acquired Opexa Assets, February 2017
  8. Brammer Bio – Formed through Merger of Brammer Biopharmaceuticals and Florida Biologix
  9. CCRM – Built a 10,000 ft² Centre for Advanced Therapeutic Cell Technologies supported by CAD $40M from GE and FedDev Ontario
  10. ACG Asahi Glass – Bought German CDMO company Biomeva in September 2016
  11. Roslin Cell Therapies, a Subsidiary of Roslin Cells
  12. Akron Biotech – Develops and manufactures ancillary materials and novel products/tools under cGMP compliance for tissue, cell and gene therapies
  13. apceth Biopharm
  14. Cognate Bioservices, Inc.
  15. MEDINET Co. Ltd.
  16. The Clinical Trial Company (TCTC)
  17. Praxis Pharmaceutical
  18. Cellular Therapeutics Ltd. (CTL)
  19. CTI Clinical Trial and Consulting
  20. Eufets GmbH
  21. Fraunhofer Gesellschaft
  22. Cellforcure SASU
  23. Molmed S.p.A.
  24. Advent Bioservices Ltd 
  25. Gravitas Biomanufacturing 
  26. Cell Therapies Pty Ltd (CTPL)

Table of Contents

  1. Definitions
  2. Methodology
  3. List of Cell Therapy CDMO Market Participants
  4. Reference Data for the Cell Therapy CDMO Market
  5. Market Share Breakdown
  6. Summary of Market Breakdown
  7. Market Size Determination
  8. Five-Year Market Forecasts (through 2022)

Claim it now and get immediate access. Of course, your investment is backed by a 60-Day Money Back Guarantee.

4.7 / 5 ( 83 votes )

$197

Related products

  • Job Posting on BioInformant

    Job Posting on BioInformant.com – Your Perfect Hire Is In Our Audience

    $297
    Add to cart
  • U.S. Cord Blood Banking Survey

    Cord Blood Banking Survey of U.S. Parents [2017]

    $197
    Add to cart
  • US Cord Blood and Cord Tissue Storage Rates

    Rates of U.S. Cord Blood and Cord Tissue Storage – Historical and Projected

    $197
    Add to cart
  • "We are not made of drugs, we are made of cells." White T-Shirt

    “We are not made of drugs, we are made of cells.” White T-Shirt

    $29
    Select options

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • US Cord Blood and Cord Tissue Storage Rates Rates of U.S. Cord Blood and Cord Tissue Storage - Historical and Projected
    Rated 0 out of 5
    $197
  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • BioInformant Audience Reach BioInformant's Audience with Your Press Announcement
    Rated 0 out of 5
    $397 $297
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.